🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you Mark Lewis, MD, FASCO for highlighting this important fact at the #ASCO25 plenary stage that improving PFS doesn’t automatically mean improving QOL. ASCO

🧨 Slow news day? Here’s a PSA with purpose: ASCO Quality Care abstracts are due June 10. Got a trainee doing equity, policy, or QI work? Tell them to apply for a Merit Award (CV + LOR). It gives funding, visibility & momentum. Here’s how it helped me: 🔗 connection.asco.org/do/transform-y…

The NCTN, albeit imperfect, serves a critical role in advancing cancer care by: 1)Conducting pragmatic trials pharma/industry would never sponsor 2)Enrolling across a diverse network (>3K sites) representative of a “real world” population Great editorial Ted Hong Thomas George, MD, FACP, FASCO👏

Addressing Tumor Board Bad Habits and Risks: A Call for Rational Resource Management. ascopubs.org/doi/pdf/10.120… ASCO Journal of Clinical Oncology JCO Oncology Practice #CancerCare #MedEd #MedTwitter Jeffrey peppercorn MD

Claudin-18 isoform 2-specific CAR T-cell therapy vs treatment of physician’s choice for advanced GC/GJC The Lancet doi.org/10.1016/S0140-… 🔎 CT041-ST-01 phs 2 trial 👉first 🗺️randomised controlled trial of CAR T-cell therapy in solid tumours 👉Sign improved PFS ESMO - Eur. Oncology

Great discussion for fellows interested in onc meded. Fascinating discussion of what the future may look like. I agree that meded in oncology will be more digital, more active case based. We have cool ideas for workshop sessions for future experimental didactics :)

Don’t forget: many landmark trials at #ASCO25 (e.g. ATOMIC, PDIGREE, CHALLENGE) were powered by National Cancer Institute / NCTN Such studies ask high-impact, public-benefit questions that industry often won’t/can't answer. Alliance for Clinical Trials in Oncology CCTG ECOG-ACRIN Cancer Research Group NRG Oncology SWOG Cancer Research Network

100% agree. There are questions that industry cannot answer, which requires alternative mechanisms which is where the National Cancer Institute and cooperative groups come in.

Possibly one of the best matches in tennis history. Enjoy the highlights by Emirates ↘️ #RolandGarros

💯- the NCTN is complex but our trials are asking — and answering — many highly relevant questions for everyone that industry is not incentivized to answer. Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network NRG Oncology Children’s Oncology Group Nice editorial Ted Hong Thomas George, MD, FACP, FASCO academic.oup.com/jnci/advance-a…

🧠💉 Are Immune Checkpoint Inhibitors (ICIs) Safe for Patients with Neurologic Autoimmune Disorders (NAIDs)? A multicenter study of 135 cancer patients with NAIDs sheds light: 🔹 Myasthenia Gravis (MG): Highest risk — 67% had neurologic exacerbations, some severe or fatal. 🔹

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] Matthew Katz, MD 🇺🇸🟦 et al. JCO Clinical Cancer Informatics ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #ASCO25

Thanks to the incredible advocacy of PanCAN community members, 113 bipartisan members of the House signed on to the Sewell-J Joyce pancreatic cancer FY26 Dear Colleague letter to support not only restoring the dedicated Pancreatic Cancer Research Progam (PCARP) but increasing

Beyond Opioids: A Multidisciplinary Approach to #Cancer Pain Management. ascopubs.org/doi/pdf/10.120… ASCO Journal of Clinical Oncology JCO Oncology Practice #PallOnc #CancerCare #CancerResearch #SuppOnc Desiree Azizoddin, PsyD Dana-Farber

Important paper, that reinforces what our research has indicated. EOCRC is a biologically distinct disease that is not just CRC at a younger age.

GI Cancer Highlights from #ASCO25 w/ Dr. Cathy Eng ✅ #DYNAMIC3 ✅ #ATOMIC ✅ #BREAKWATER ✅ #MATTERHORN ✅ #DESTINYGastric04 Full Discussion: - oncbrothers.com/asco2025-gi - Also on the “Oncology Brothers” podcast #gism ASCO #OncTwitter #MedTwitter

🚨‼️FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests ⁦U.S. FDA⁩ fda.gov/news-events/pr…

After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research. We’re honored this year's Cattle Baron’s Ball will establish Ceci’s Fund through the American Cancer Society. Please share/donate💕 cattlebaronsball.com

Nice summary of a balanced editorial on PANOVA-3 by Mike Pishvaian. Wow – 29% dropout rate is huge, & IMO diminishes the benefits of randomization. That 40 pts in TTF arm essentially requested withdrawal after 1 mo wearing the device & weren’t included in analyses = risk for bias.

BCLC best for prognostication, not treatment algorithms #HCC